FDA Approves Vidaza for Myelodysplastic Syndromes (MDS)
Vidaza is an anticancer drug indicated for the treatment of Myelodysplastic Syndromes (MDS).Posted: May 2004
Related Articles:
- Vidaza Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS - August 21, 2008
- Pharmion Corporation Announces FDA Approval of Vidaza NDASupplement for IV Administration - January 30, 2007
- FDA Accepts Pharmion's New Drug Application for Filing and Grants Priority Review for Vidaza for the Treatment of Myelodysplastic Syndromes (MDS) - February 23, 2004
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
